ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights
08 mars 2023 17h06 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 08, 2023 (GLOBE NEWSWIRE) -- Completed all preclinical studies and manufacturing to support PMN310 IND submission to U.S. Food and Drug...
Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
08 mars 2023 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 08, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and...
ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights
14 nov. 2022 07h00 HE
|
ProMIS Neurosciences Inc.
Closed US$7.4 million private placementAppointed Gail Farfel, Ph.D., as Chief Executive OfficerContinued progress toward investigational new drug (IND) submission for PMN310 to pursue Alzheimer’s...
ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement
12 oct. 2022 07h00 HE
|
ProMIS Neurosciences Inc.
Toronto, Ontario and Cambridge, MA, Oct. 12, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer
13 sept. 2022 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts , Sept. 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and...
ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results
15 août 2022 17h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 15, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on...
ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference
02 août 2022 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference
27 juil. 2022 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”
08 juil. 2022 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 08, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on...
PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA
27 juin 2022 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, MA, June 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...